某院2010-2014年抗乙肝病毒药物使用分析
x

请在关注微信后,向客服人员索取文件

篇名: 某院2010-2014年抗乙肝病毒药物使用分析
TITLE:
摘要: 目的:为临床合理使用抗乙肝病毒(HBV)药物提供参考。方法:对某院2010-2014年抗HBV药物的销售金额、用药频度(DDDs)、序号比(B/A)等进行回顾性统计分析。结果:该院2010-2014年抗HBV药物销售总金额由569.82万元逐年上升至2 011.56万元,其中恩替卡韦增长最为明显,年均增长率(AARG)为76.37%,普通干扰素金额逐年下降,AARG为-20.30%。除普通干扰素的DDDs逐年下降外,其余各类抗HBV药物的DDDs均呈增长趋势,其中恩替卡韦增幅最为明显,2010-2014年,增长率为1 366.30%。拉米夫定、替比夫定和普通干扰素B/A值连续5年均处于等于1或接近1的水平,用药人数与销售金额同步性较好。结论:核苷(酸)类似物已经成为乙型肝炎抗病毒治疗的重要方法,临床治疗中应根据患者的具体情况合理选择药物,以提高治疗的安全性、有效性和经济性。
ABSTRACT: OBJECTIVE: To provide reference for rational use of antiviral drugs for hepatitis B viral (HBV) in the clinic. METHODS: The application of antiviral drugs for HBV in a hospital during 2010-2014 was analyzed statistically in respects of consumption sum, DDDs, serial number ratio(B/A), etc. RESULTS: Total consumption sum of antiviral drugs for HBV in a hospital increased from 5 698 200 yuan to 20 115 600 yuan during 2010-2014, and annual average rate of growth (AARG) of entecavir 76.37%. The consumption sum of ordinary interferon decreased year by year, with AARG of -20.30%. Besides DDDs of ordinary interferon declined year by year, DDDs of all antiviral drugs for HBV showed a trend of increased year by year, among which the increase of entecavir was the most obvious, being 1 366.30% from 2010 to 2014. The B/A value of lamivudine, telbivudine and ordinary interferon were equal to or close to 1 for consecutive 5 years, and the number of patients was well synchronized with consumption sum. CONCLUSIONS: Nucleoside (acid) analogues has become an important method of HBV antiviral treatment, and the drugs should be selected reasonably according to the specific condition of patients in clinical treatment, in order to improve the safety, effectiveness and economy of treatment.
期刊: 2016年第27卷第5期
作者: 翁蒋丽,赵卫国,劳国琴
AUTHORS: WENG Jiangli,ZHAO Weiguo,LAO Guoqin
关键字: 抗乙肝病毒药物;核苷(酸)类似物;干扰素;用药分析
KEYWORDS: Antiviral drugs for hepatitis B viral; Nucleoside (acid) analogues; Interferons; Analysis of drug use
阅读数: 181 次
本月下载数: 3 次

* 注:未经本站明确许可,任何网站不得非法盗链资源下载连接及抄袭本站原创内容资源!在此感谢您的支持与合作!